{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Control+Capsules&page=104",
    "query": {
      "intervention": "Control Capsules",
      "page": 104
    },
    "page_size": 10
  },
  "pagination": {
    "page": 104,
    "page_size": 10,
    "total_count": 2912,
    "total_pages": 292,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Control+Capsules&page=105&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Control+Capsules&page=103&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-10T02:12:56.813Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03796962",
      "title": "A Study to Evaluate XEN1101 as Adjunctive Therapy in Focal Epilepsy",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Focal Epilepsy"
      ],
      "interventions": [
        {
          "name": "XEN1101",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Xenon Pharmaceuticals Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 325,
      "start_date": "2019-01-30",
      "completion_date": "2030-10",
      "has_results": true,
      "last_update_posted_date": "2026-11-05",
      "last_synced_at": "2026-11-10T02:12:56.813Z",
      "location_count": 54,
      "location_summary": "Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 46 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "La Jolla",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03796962"
    },
    {
      "nct_id": "NCT02153983",
      "title": "Effects of Colchicine in Non-Diabetic Adults With Metabolic Syndrome",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Obesity",
        "Metabolic Disease"
      ],
      "interventions": [
        {
          "name": "Colchicine 0.6Mg Cap",
          "type": "DRUG"
        },
        {
          "name": "Placebo capsules given",
          "type": "DRUG"
        },
        {
          "name": "Colchicine 0.6Mg Tab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 77,
      "start_date": "2014-05-31",
      "completion_date": "2018-08-15",
      "has_results": true,
      "last_update_posted_date": "2019-08-13",
      "last_synced_at": "2026-11-10T02:12:56.813Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02153983"
    },
    {
      "nct_id": "NCT01163032",
      "title": "Efficacy and Safety of Tasimelteon Compared With Placebo in Totally Blind Subjects With Non-24-Hour Sleep-Wake Disorder",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Non-24-Hour Sleep-Wake Disorder"
      ],
      "interventions": [
        {
          "name": "tasimelteon",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vanda Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 136,
      "start_date": "2010-08",
      "completion_date": "2012-11",
      "has_results": true,
      "last_update_posted_date": "2014-10-16",
      "last_synced_at": "2026-11-10T02:12:56.813Z",
      "location_count": 23,
      "location_summary": "Phoenix, Arizona • Orange, California • Palo Alto, California + 20 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01163032"
    },
    {
      "nct_id": "NCT02178098",
      "title": "Evaluation of ETC-1002 in Participants With Hypercholesterolemia and Hypertension",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hypercholesterolemia",
        "Hypertension"
      ],
      "interventions": [
        {
          "name": "ETC-1002",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Esperion Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 143,
      "start_date": "2014-06-16",
      "completion_date": "2015-05-22",
      "has_results": true,
      "last_update_posted_date": "2023-04-04",
      "last_synced_at": "2026-11-10T02:12:56.813Z",
      "location_count": 43,
      "location_summary": "Birmingham, Alabama • Muscle Shoals, Alabama • Chandler, Arizona + 34 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Muscle Shoals",
          "state": "Alabama"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02178098"
    },
    {
      "nct_id": "NCT04639193",
      "title": "Combination Drug-Therapy for Patients With Untreated Obstructive Sleep Apnea",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "OSA",
        "Obstructive Sleep Apnea"
      ],
      "interventions": [
        {
          "name": "Acetazolamide",
          "type": "DRUG"
        },
        {
          "name": "Eszopiclone",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Venlafaxine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, San Diego",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 20,
      "start_date": "2020-12-01",
      "completion_date": "2022-01-27",
      "has_results": true,
      "last_update_posted_date": "2024-05-29",
      "last_synced_at": "2026-11-10T02:12:56.813Z",
      "location_count": 2,
      "location_summary": "La Jolla, California",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04639193"
    },
    {
      "nct_id": "NCT06258265",
      "title": "A Study of TAK-279 in Healthy Adults on the Effect on ECG Measurements",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "TAK-279",
          "type": "DRUG"
        },
        {
          "name": "TAK-279 Placebo",
          "type": "DRUG"
        },
        {
          "name": "Moxifloxacin",
          "type": "DRUG"
        },
        {
          "name": "Moxifloxacin Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Takeda",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 120,
      "start_date": "2024-04-29",
      "completion_date": "2024-07-09",
      "has_results": false,
      "last_update_posted_date": "2024-07-11",
      "last_synced_at": "2026-11-10T02:12:56.813Z",
      "location_count": 1,
      "location_summary": "Tempe, Arizona",
      "locations": [
        {
          "city": "Tempe",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06258265"
    },
    {
      "nct_id": "NCT04452565",
      "title": "NA-831, Atazanavir and Dexamethasone Combination Therapy for the Treatment of COVID-19 Infection",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Coronavirus Infection",
        "Severe Acute Respiratory Infection",
        "Severe Acute Respiratory Syndrome Coronavirus 2"
      ],
      "interventions": [
        {
          "name": "Drug: NA-831",
          "type": "DRUG"
        },
        {
          "name": "NA-831 and Atazanavir",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "NA-831and Dexamethasone",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Atazanavir and Dexamethasone",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "DRUG",
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "Biomed Industries, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 525,
      "start_date": "2022-06-15",
      "completion_date": "2023-12-15",
      "has_results": false,
      "last_update_posted_date": "2022-02-16",
      "last_synced_at": "2026-11-10T02:12:56.813Z",
      "location_count": 31,
      "location_summary": "Los Angeles, California • Orange, California • Palo Alto, California + 27 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04452565"
    },
    {
      "nct_id": "NCT03110133",
      "title": "Efficacy, Safety, and Tolerability Study of Oral Full-Spectrum MicrobiotaTM (CP101) in Subjects With Recurrent C. Diff",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Clostridium Difficile Infection Recurrence"
      ],
      "interventions": [
        {
          "name": "Full Spectrum Microbiota",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Finch Research and Development LLC.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 206,
      "start_date": "2017-05-08",
      "completion_date": "2020-06-18",
      "has_results": true,
      "last_update_posted_date": "2022-10-05",
      "last_synced_at": "2026-11-10T02:12:56.813Z",
      "location_count": 54,
      "location_summary": "Scottsdale, Arizona • Los Angeles, California • Murrieta, California + 48 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Murrieta",
          "state": "California"
        },
        {
          "city": "Oakland",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03110133"
    },
    {
      "nct_id": "NCT04499963",
      "title": "Trial of Theracurmin for Patients With Amyotrophic Lateral Sclerosis (ALS)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Amyotrophic Lateral Sclerosis"
      ],
      "interventions": [
        {
          "name": "Theracurmin HP",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Richard Bedlack, M.D., Ph.D.",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 100,
      "start_date": "2020-08-28",
      "completion_date": "2022-08-30",
      "has_results": true,
      "last_update_posted_date": "2023-09-28",
      "last_synced_at": "2026-11-10T02:12:56.813Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04499963"
    },
    {
      "nct_id": "NCT07535034",
      "title": "A Phase 2 Trial of Dotinurad in Xanthine Oxidase Inhibitor (XOI) Intolerant/Uricase Failure Gout Participants",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Gout"
      ],
      "interventions": [
        {
          "name": "Dotinurad",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Crystalys Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 90,
      "start_date": "2026-05-08",
      "completion_date": "2027-08",
      "has_results": false,
      "last_update_posted_date": "2026-09-28",
      "last_synced_at": "2026-11-10T02:12:56.813Z",
      "location_count": 41,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 37 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Granada Hills",
          "state": "California"
        },
        {
          "city": "Thousand Oaks",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07535034"
    }
  ]
}